Project Grant R01CA292019
Award Date
8/12/24
Completion Date
7/31/29
Dollars Obligated
$679K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Cancer Institute (NCI) awarded a Project Grant under the CFDA 93.394 Cancer Detection and Diagnosis Research program to Exai Bio Inc., a small disadvantaged business located in Palo Alto, California. The $1,280,908 grant, awarded on September 12, 2024, supports the development of a novel liquid biopsy assay and artificial intelligence (AI) model for early detection of non-small cell lung cancer (NSCLC) and prediction of cancer subtypes. The project aims to gather samples and test...
The National Cancer Institute (NCI) awarded a 4-year, $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, WA for the "RARECYTEFINDER" project. The goal of this project is to develop an advanced, label-free method for the unbiased identification and comprehensive molecular analysis of rare disseminated tumor cells (DTCs) present in liquid and tissue biopsy specimens across various solid tumor types. The...
The National Cancer Institute (NCI) awarded a $680,433 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to The Regents of the University of California, San Francisco (UCSF) to conduct a multi-year research project titled "Multimodality Spatial Analysis in Prostate Cancer to Improve Prognostic Estimation and Cast Light into the Black Box of Pathology Artificial Intelligence Algorithms." The goal of this research is to apply cutting-edge spatial proteogenomic...
This Project Grant award from the National Cancer Institute (CFDA 93.394, Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) provides $391,703 from May 1, 2025 to April 30, 2028 to develop rapid, sensitive, and reproducible platforms for screening drugs in a preclinical setting using patient-derived breast cancer organoids. The project aims to improve the uniformity, reproducibility, and physiological relevance of organoid models to...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing...
The National Cancer Institute (NCI) awarded a $676,006 federal Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) for the project "Early Identification of Immunotherapy Resistance Through Integrated Multiparameter Imaging". The 5-year project aims to develop non-invasive imaging strategies, including PET and implantable fluorescence sensors, to monitor response and identify mechanisms of...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Leland Stanford Junior University (Stanford University) for $170,376. The grant, awarded on April 9, 2025, supports the development of a rapid, label-free, and cost-effective technique to quantify chimeric antigen receptor (CAR) T cells in patient blood samples using surface-enhanced Raman spectroscopy (SERS) and machine learning. This research aims to...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...